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germline mutations causing the disease in some of the cases (Foulkes
et al., 2014). This report describes the ﬁrst instance of genetic counsel-
ing and prophylactic bilateral oophorectomy based on mutational anal-
ysis of the SMARCA4 gene in familial SCCOHT.
Case
This patient is a 33 year old Caucasian mother of three teenage boys.
Three female relatives had previously been diagnosed with SCCOHTIntroduction
Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a
highly lethal ovarian malignancy that occurs in young women (average
age 24) (Young et al., 1994). The early age of onset and familial aggrega-
tion of some cases suggest a hereditary cause (Young et al., 1994). These
undifferentiated cancers are comprised of small hyperchromatic cells
with briskmitotic activity, and can be difﬁcult to distinguishmorpholog-
ically fromother undifferentiated tumors. Based on theirmicroscopic ap-
pearance, SCCOHTs have been referred to as rhabdoid tumors, however,
their cell of origin is unknown. Approximately 60% of SCCOHTs present
with hypercalcemia and some have been shown to express parathyroid
hormone-related protein (Young et al., 1994). The primary ovarian tu-
mors are almost always unilateral and roughly half are metastatic at di-
agnosis. Even among stage IA cases, ﬁve year survival is only 33%
(Young et al., 1994).
Our group and others recently reported that inherited and sporadic
mutations in the SMARCA4 gene, which encodes the BRG1 protein (a
component of the SWI/SNF chromatin remodeling complex), are the
major cause of SCCOHT (Witkowski et al., 2014). SCCOHT arising in
SMARCA4 mutation carriers does not express immunohistochemically
detectable BRG1. It also has been shown that other members of the
SWI/SNF family are frequently mutated in various types of cancers
(Wang et al., 2014). Of relevance to SCCOHT, SMARCA4, or the relatedology, Duke University Medical
.
. This is an open access article under(ages 26, 24 and 12 years) and two had died of the disease (Witkowski
et al., 2014). We recently reported identiﬁcation of the causative
SMARCA4mutation in the affected women in this family, c.2617-3 CNT
(Witkowski et al., 2014). This mutation results in a truncated protein
that is subject to nonsense-mediated decay and was accompanied by a
deleteriousmutation in the other allele in the tumor. In view of the posi-
tion of this patient in the pedigree and the known age distribution at di-
agnosis of SCCOHT (14 months to 47 years) (Young et al., 1994), we
offered her genetic testing, resulting in the identiﬁcation of the known
familial mutation. Prior to genetic testing, we discussed the possibility
of prophylactic bilateral oophorectomy. We explained that the risk of
SCCOHT for carriers of deleterious mutations in SMARCA4 has not yet
been well quantiﬁed, but the penetrance appears to be fairly high. We
also noted the three cases of SCCOHT in this family, all conﬁrmed by pa-
thology report (Witkowski et al., 2014). The patient elected to undergo
total laparoscopic hysterectomy and bilateral salpingo-oophorectomy,
and the procedure was completed uneventfully. She received estrogen
replacement therapy post-operatively. The ovaries were serially sec-
tioned and examined by a gynecologic pathologist to look for evidence
of premalignant or early malignant changes, but none were found. Im-
munohistochemical staining of multiple sections of both ovaries did
not reveal loss of BRG1 expression in the ovarian stroma, follicles, or
epithelium.Discussion
Current evidence suggests that inherited forms of SCCOHT may be
more common than previously thought (Foulkes et al., 2014). Given
the rarity of these tumors, expert pathology consultation is appropriate
in verifying the diagnosis, which can be facilitated by demonstration of
loss of BRG1 immunostaining in tumor nuclei. Although inmany tumorsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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germline and others in the familymay also be carriers. In view of this, ge-
netic counseling andmutational analysis of the SMARCA4 gene should be
offered to families affected by SCCOHT. Mutational analysis can be per-
formed in academic centers and commercially and should be covered
by insurance. The penetrance of germline mutations for SCCOHT is difﬁ-
cult to estimate, but appears to be considerable. Identiﬁcation and
counseling of male SMARCA4 mutation carriers are also important, as
their daughtersmay inherit themutation. It is unclear whether germline
SMARCA4mutations increase the risk of other types of cancers inwomen
ormen, but somatic mutations in this gene have been found in lung can-
cer, medulloblastoma and Burkitt lymphoma (Wang et al., 2014).
Most patients with SCCOHT present with a pelvic mass. In the ab-
sence of a known family history of the disease, unilateral oophorectomy
is usually performed in thosewith stage I disease. A deﬁnitive diagnosis
of SCCOHT is unlikely to be rendered on intraoperative frozen section
and most of these cases occur well prior to the onset of menopause or
completion of childbearing. If the ﬁnal pathology report shows
SCCOHT, immunostainining for BRG1 should be performed in the
tumor. Germline genetic testing should be recommended if there is a
loss of BRG1 expression (Fig. 1). Mutational analysis of the cancer and
demonstration of a somatic mutation and loss of heterozygosity in the
other allele may also be helpful to identify somatic SMARCA4mutations
and will provide assurance that a germline mutation was not missed
(Fig. 1). If the mutation is somatic, a second surgery to remove the
other ovary is not needed in stage IA cases, as the contralateral ovary
should not be at increased risk for SCCOHT. If a germline mutation is
found, removal of the other ovary should be strongly considered.
It is instructive to compare the role of prophylactic surgery in
SMARCA4 carriers to its more established role in preventing high grade
serous cancers of the ovary, fallopian tube and peritoneum in BRCA1/2
mutation carriers. In view of the high lethality of serous cancers and
lack of effective early detection methods, it is recommended that pro-
phylactic bilateral salpingo-ophorectomy be performed after age 35,
when the risk of high grade serous cancers begins to rise in carriers
(Finch et al., 2014). In contrast, delaying prophylactic oophorectomy
in those with stage I SCCOHT and in unaffected SMARCA4 carriers until
childbearing is complete seems risky in view of the young age of onsetFig. 1. Proposed clinical algorithm for management of small ceand high lethality of this disease. Although screening and early detec-
tion using imaging techniques might be an alternative prior to prophy-
lactic bilateral oophorectomy, this may not reduce mortality from a
cancer such as SCCOHT with its high propensity for metastasis. Howev-
er, it is possible that these tumors, which arise as a mass in the ovary,
may be easier to detect at an early stage using imaging than BRCA1/2 as-
sociated cancers that primarily arise and spread from the fallopian tube
epithelium. Since no cases of SCCOHT have been reported after age 45, it
may be reasonable to perform preventive oophorectomy only opportu-
nistically in older SMARCA4 mutation carriers who are having surgery
for other indications.
Careful gross and microscopic examination should be performed in
prophylactically removed ovaries of SMARCA4 carriers to look for a pre-
malignant or malignant lesion. Nonewere seen in this case, nor has this
been reported in the literature (Young et al., 1994), but this is the ﬁrst
prophylactic surgery reported for this disease and lesions may be
found with additional experience. The cell of origin of SCCOHT is un-
known, but these cancers clearly arise from the ovary, perhaps from
some type of stem cell. The SMARCA4mutation carrier who underwent
prophylactic surgery in this case report was 33 years old and was fortu-
nate to not have already developed SCCOHT. Hopefully in the future,
carriers will be identiﬁed at much earlier ages when prophylactic sur-
gery can be performed while the prevention of SCCOHT is likely to be
most effective. The degree towhich very young unaffected carriers, par-
ticularly those who are prepubertal, can participate along with their
parents in making this difﬁcult decision will vary based on their age
and maturity.
SMARCA4 mutation carriers will increasingly be identiﬁed in
childhood and early adolescence and should then be counseled about
prophylactic oophorectomy, but many will not have chosen a partner
or considered conception. Ovarian hyperstimulation and immediate
in vitro fertilization are not realistic options in most circumstances.
There has been substantial improvement in pregnancy rates using cryo-
preserved oocytes due to improved methods with vitriﬁcation that in-
volve more rapid freezing (Cil and Seli, 2013). Because success rates
are similar to those using conventional in vitro fertilization, oocyte cryo-
preservation is no longer considered experimental for medical indica-
tions such as cancer (Loren et al., 2013). This may represent the bestll carcinoma of the ovary, hypercalcemic type (SCCOHT).
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is not ready to conceive could undergo ovarian hyperstimulation and
oocyte harvest prior to prophylactic bilateral oophorectomy with uter-
ine preservation for future pregnancy via delayed in vitro fertilization.
To prevent genetic transmission of the mutation, preimplantation ge-
netic diagnosis of the ﬁrst polar body prior to oocyte cryopreservation
or of a subsequent embryo would be recommended (Keskintepe et al.,
2009). Since there are case reports of SCCOHT prior to puberty, prophy-
lactic bilateral oophorectomy could conceivably be considered in some
SMARCA4 mutation carriers prior to menarche. In such cases, oocyte
harvest and cryopreservation would not be feasible, but the uterus
could be left in place for subsequent pregnancy using donor oocytes.
Although pregnancies have been reported after cryopreservation of
ovarian tissue with subsequent reimplantation, the success rate is
much lower and this is still considered experimental. An additional con-
cern is that this could transplant cancer cells back into the patient. This
is particularly problematic in SCCOHT,where the heightened cancer risk
is speciﬁc to the ovary.
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